Navigation Links
Promising Data Presented on GenVec Malaria Program
Date:11/14/2012

s such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expen
'/>"/>

SOURCE GenVec, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
2. New 3-D transistors promising future chips, lighter laptops
3. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
4. University of Miami study finds RBAC to possess promising immunomodulating effects with respect to natural killer cell and cytokine activity
5. A New Mechanism for Tau Protein Pathology in Alzheimers Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Startling results in synthetic chemistry presented in Nature Chemistry
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. New Boehringer Ingelheim Oncology Data to be Presented at ESMO 2012 Congress
10. Top Contenders For the First Annual 2012 Fright Night Awards Presented By Cancer Bites Announced
11. GenVec Achieves Second Milestone in Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... October 02, 2014 Freeslate, ... research solutions for biopharmaceutical development, today announced highlights ... 24, 2014 at GlaxoSmithKline (GSK) in Ware, UK. ... of best practices in high throughput research and ... leaders gathered together to discuss the challenges and ...
(Date:10/2/2014)... The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama's BRAIN (Brain Research ... effort to revolutionize our understanding of the human ...
(Date:10/2/2014)... , Oct. 2, 2014  NKT Therapeutics ... Administration has granted Fast Track designation to NKTT120, ... treatment of sickle cell disease.  NKTT120 is a ... a regulatory T cell that has been demonstrated ... in preclinical models of sickle cell disease.  Fast ...
(Date:10/1/2014)... 01, 2014 METTLER TOLEDO’s newly improved ... precision balances as well as a dual range ... performance, the new SmartPan™ weighing pan delivers results up ... On all balances, ergonomic design details mean users no ... working for long periods in front of the balance. ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 3, 2011 Asmacure Ltee, a clinical-stage ... agonists for the treatment of asthma and other inflammatory ... as chief executive officer.  With a solid foundation established ... it progresses its lead compound, a potential new treatment ...
Cached Biology Technology:Reportlinker Adds Orthopedic Biomaterials, The World Market 2Reportlinker Adds Orthopedic Biomaterials, The World Market 3Reportlinker Adds Orthopedic Biomaterials, The World Market 4EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... criminals, requires evidence and witnesses; but on the scale ... easier said than done. A team of ... Arizona State University may soon change that. Under a ... a new way to close the gaps in the ...
... Sarasota FL., December 17, 2007 Researchers at ... of the EASE (Exhale Airway Stents for Emphysema) Trial, ... treatment that may offer a significant new, minimally-invasive option ... focuses on a procedure called airway bypass that involves ...
... latest American Chemical Society (ACS) News Service Weekly PressPac with ... News.,Please credit the individual journal or the American Chemical Society ... FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed for ... ARTICLE #1 FOR IMMEDIATE RELEASE A faster, ...
Cached Biology News:ASU researchers use NASA satellites to improve pollution modeling 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 3American Chemical Society's Weekly PressPac -- Dec. 12, 2007 4American Chemical Society's Weekly PressPac -- Dec. 12, 2007 5American Chemical Society's Weekly PressPac -- Dec. 12, 2007 6American Chemical Society's Weekly PressPac -- Dec. 12, 2007 7American Chemical Society's Weekly PressPac -- Dec. 12, 2007 8American Chemical Society's Weekly PressPac -- Dec. 12, 2007 9American Chemical Society's Weekly PressPac -- Dec. 12, 2007 10
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: